Shares of the AdvisorShares Pure US Cannabis ETF (MSOS) have climbed to their highest levels of 2026, and the timing is not an accident. Investors are positioning ahead of a June 29 DEA administrative hearing that could reshape how the federal government treats marijuana, while Trulieve Cannabis Corp's move to the New York Stock Exchange gives the sector its clearest proof yet that senior-exchange access is now within reach for multi-state operators. As of May 31, MSOS delivered a 103.7% one-year NAV return, well ahead of the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%. The fund managed $1.13 billion in assets as of June 5.
The fundamentals behind this rally sit well outside Wall Street, though. Every retail operator running budroom inventory through METRC, reconciling POS terminals at close, or fighting 280E's disallowance of ordinary business deductions understands why a Schedule III move matters more than any stock chart. Operators from single-location dispensaries to multi-state chains have spent years absorbing tax bills that alcohol retailers never face, simply because cannabis remains federally scheduled alongside substances with no accepted medical use. That gap has shaped everything from wholesale pricing to how software vendors build compliance logs into point of sale cannabis dispensary minnesota systems and similar platforms across other regulated markets, since every transaction has to satisfy state seed-to-sale tracking on top of ordinary retail accounting. point of sale cannabis dispensary minnesota
Why Trulieve's Listing Signals More Than One Company's Milestone
Trulieve, MSOS' largest holding at roughly 30% of assets, separated its medical cannabis operations from its adult-use business specifically to satisfy senior exchange listing standards. CEO Kim Rivers called it a historic step, and CEO framing aside, the mechanics matter: NYSE and Nasdaq have long treated federally illegal adult-use cannabis revenue as a listing obstacle, pushing multi-state operators onto Canadian exchanges or OTC markets with thinner liquidity and higher capital costs. A structural workaround that isolates medical revenue streams gives other operators a template. Cresco Labs' $50 million revolving credit facility from Needham Bank, disclosed this week, points the same direction: non-dilutive financing that CEO Charlie Bachtell says positions the company for U.S. capital markets access and a future uplisting.
What the Rescheduling Hearing Actually Decides
The hearing set for June 29 will examine whether broader cannabis products, not just state-licensed medical marijuana, should move to Schedule III. That follows Acting Attorney General Todd Blanche's April action reclassifying medical marijuana products, which eliminated 280E tax penalties for licensed medical operators and let them deduct payroll, rent and interest like any other business. Trump's formal nomination of Blanche to the permanent attorney general post this week reinforced investor confidence that the rescheduling track will continue. Roth Capital called the move "extremely favorable" for the sector, citing benefits across taxation, capital access and future uplistings. Fair enough - but a Schedule III designation would not legalize adult-use cannabis federally, and interstate commerce, banking access under the Bank Secrecy Act, and advertising restrictions would remain largely unresolved even after a favorable ruling.
Reading the Upside Numbers With Some Caution
Analyst price targets compiled from Koyfin data show Verano at roughly 195% implied upside, Jushi Holdings near 183%, and Cresco Labs close to 99% - all larger than Trulieve's 27% or Curaleaf's 13%. Green Thumb Industries, among the ETF's bigger positions, shows about 70% upside. These figures reflect analyst price targets against current share prices, not guaranteed returns, and cannabis equities have a history of sharp reversals when regulatory timelines slip. Retail sentiment on platforms like Stocktwits running "extremely bullish" on heavy message volume is a mood indicator, not a fundamental one. For operators and suppliers watching this rally from the retail floor rather than a brokerage account, the real signal is whether rescheduling translates into lower effective tax rates, better banking terms, and eventually interstate wholesale opportunities - outcomes that would matter far more to dispensary economics than any single stock's quarterly move.
